Valeant Defends Itself As Legal Structures Test New LimitsMark Melin
Saying Citron Research’s motivation for issuing research that shined a spotlight on potential issues at Valeant Pharmaceuticals, Mike Pearson, Valeant's chief executive officer, characterized the short-seller's research as “similar to someone running into a theater and yelling fire.” The report, issued late . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.